Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18777836 | C-BASED SINGLE DOMAIN ANTIBODY FOR NEUTRALIZING RESPIRATORY SYNCYTIAL VIRUS AND APPLICATION THEREOF | July 2024 | April 2025 | Allow | 9 | 1 | 0 | No | No |
| 18512036 | MULTIPLEXED NUCLEIC ACID DETECTION KIT FOR HUMAN PAPILLOMAVIRUS (HPV) TYPING, AND DETECTION METHOD | November 2023 | August 2024 | Allow | 9 | 1 | 0 | No | No |
| 18277087 | Recombinant Severe Acute Respiratory Syndrome Coronavirus 2 Rbd Trimer Protein Vaccine Capable Of Generating Broad-Spectrum Cross Neutralization Activity, and Preparation Method and Use Thereof | August 2023 | April 2025 | Allow | 20 | 2 | 0 | No | No |
| 18227747 | METHODS OF MANUFACTURING GENETICALLY-MODIFIED LYMPHOCYTES | July 2023 | November 2024 | Abandon | 16 | 1 | 0 | No | No |
| 17827320 | SYNTHETIC CHIMERIC POXVIRUSES | May 2022 | November 2024 | Allow | 29 | 1 | 0 | No | No |
| 17737991 | ATTENUATING VIRAL MUTATIONS IN PROTEIN GENES | May 2022 | March 2025 | Allow | 34 | 3 | 0 | No | No |
| 17717504 | RECOMBINANT RSV LIVE VACCINE STRAIN AND THE PREPARING METHOD THEREOF | April 2022 | February 2025 | Allow | 34 | 2 | 0 | No | No |
| 17578049 | AMINO ACID SEQUENCE DERIVED FROM S PROTEIN OF SARS-COV2 FOR GENERATING AN ANTI-SARS -COV-2 ANTIBODY | January 2022 | March 2025 | Allow | 37 | 3 | 0 | No | No |
| 17513538 | HIGH THROUGHPUT IMMUNOASSAYS AND METHODS FOR THE DETECTION OF SARS-COV-2 ANTIGENS | October 2021 | November 2024 | Abandon | 36 | 2 | 0 | No | No |
| 17593446 | A LIVE AND ATTENUATED FLAVIVIRUS COMPRISING A MUTATED M PROTEIN | September 2021 | June 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17436782 | FILOVIRUS ANTIBODIES AND METHODS | September 2021 | December 2024 | Allow | 39 | 1 | 0 | No | No |
| 17434489 | Multivalent Live-attenuated Influenza Vaccine for Prevention and Control of Equine Influenza Virus (EIV) in Horses | August 2021 | March 2025 | Allow | 42 | 1 | 0 | No | No |
| 17400041 | ADENO-ASSOCIATED VIRUS VARIANT CAPSIDS AND METHODS OF USE THEREOF | August 2021 | December 2024 | Allow | 40 | 2 | 0 | No | No |
| 17430018 | RECOMBINANT HERPES SIMPLEX VIRUS HAVING MODIFIED GLYCOPROTEIN GH FOR RETARGETING AND USE THEREOF | August 2021 | December 2024 | Allow | 40 | 2 | 0 | No | No |
| 17427844 | IN VITRO METHOD FOR THE DIAGNOSIS OF VIRAL INFECTIONS | August 2021 | December 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17427569 | IMMUNOCHROMATOGRAPHY ANALYSIS DEVICE FOR DETECTING DENGUE VIRUS | July 2021 | January 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17389724 | ANTI-CORONAVIRUS VACCINES | July 2021 | January 2025 | Allow | 41 | 2 | 1 | No | No |
| 17387409 | METHOD FOR MEASURING VIRAL ANTIGEN IN SAMPLE, ANTIBODY SET, AND REAGENT KIT | July 2021 | March 2025 | Allow | 43 | 2 | 0 | Yes | No |
| 17426043 | PRODUCTION OF VIRUSES IN CONTINUOUSLY GROWING EPITHELIAL CELL LINES DERIVED FROM CHICKEN GUT | July 2021 | February 2025 | Allow | 43 | 1 | 0 | No | No |
| 17425791 | POLYPEPTIDES DIRECTED AGAINST VIRAL INFECTION AND USES THEREOF | July 2021 | March 2025 | Allow | 43 | 1 | 0 | No | No |
| 17425534 | METHODS FOR SCREENING POLYPEPTIDES CAPABLE OF BINDING SPECIFIC TARGET MOLECULES AND TOOLS RELATED THERETO | July 2021 | July 2025 | Allow | 47 | 2 | 0 | Yes | No |
| 17425618 | SEED CULTURE PROCESS FOR AAV PRODUCTION | July 2021 | January 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17305796 | VIROFIND: A NOVEL PLATFORM FOR DETECTION AND DISCOVERY OF THE ENTIRE VIROGENOME IN CLINICAL SAMPLES | July 2021 | November 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17421816 | USE OF HLA-A*11:01-RESTRICTED HEPATITIS B VIRUS (HBV) PEPTIDES FOR IDENTIFYING HBV-SPECIFIC CD8+ T CELLS | July 2021 | April 2025 | Allow | 46 | 2 | 0 | No | No |
| 17421541 | FOOT-AND-MOUTH DISEASE VIRUS-LIKE PARTICLE ANTIGEN, AND VACCINE COMPOSITION, PREPARATION METHOD, AND APPLICATION THEREOF | July 2021 | December 2024 | Allow | 42 | 2 | 0 | Yes | No |
| 17414759 | SERUM-FREE MEDIUM FOR AVIAN VACCINE PRODUCTION AND USES THEREOF | June 2021 | June 2025 | Allow | 48 | 3 | 0 | No | No |
| 17413853 | PATHOGEN-ASSOCIATED MOLECULAR PATTERN MOLECULES AND RNA IMMUNOGENIC COMPOSITIONS AND METHODS OF USING THE COMPOSITIONS FOR TREATING CANCER | June 2021 | January 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17413203 | HETEROLOGOUS PRIME BOOST VACCINE COMPOSITIONS AND METHODS | June 2021 | March 2025 | Abandon | 45 | 2 | 0 | No | No |
| 17413228 | PRODUCTION OF VIRAL VACCINES ON AN AVIAN CELL LINE | June 2021 | November 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17299520 | ENGINEERED HANSENULA FUNGI EFFICIENTLY EXPRESSING CA10 VIRUS-LIKE PARTICLES AND USES THEREOF | June 2021 | November 2024 | Allow | 42 | 2 | 0 | Yes | No |
| 17293364 | STABILIZED PRE-FUSION RSV F PROTEINS | May 2021 | February 2025 | Allow | 45 | 2 | 0 | No | No |
| 17289336 | SYSTEM FOR PROTEIN INACTIVATION AND RECOMBINANT PHAGES FOR TARGETED BACTERIAL KILLING, INFECTION, BIODETECTION, AND AS A MEANS OF PROTEIN EXTRACTION | April 2021 | October 2024 | Allow | 41 | 1 | 0 | No | No |
| 17231415 | SIV ENVELOPE TRIMER | April 2021 | December 2024 | Allow | 44 | 2 | 0 | Yes | No |
| 17269955 | COMPOSITIONS AND METHODS FOR MODULATING TRANSDUCTION EFFICIENCY OF ADENO-ASSOCIATED VIRUSES | February 2021 | August 2024 | Allow | 42 | 1 | 1 | No | No |
| 17261501 | METHODS FOR SCREENING AND IDENTIFYING AGENTS THAT INHIBIT OR MODULATE THE NUCLEAR EGRESS COMPLEX OF HERPESVIRUSES | January 2021 | October 2024 | Allow | 45 | 1 | 0 | No | No |
| 17055151 | VIRUS VECTOR PRODUCTION | November 2020 | March 2025 | Allow | 52 | 2 | 0 | Yes | No |
| 17050608 | SCALABLE CLARIFICATION PROCESS FOR RECOMBINANT AAV PRODUCTION | October 2020 | March 2025 | Allow | 52 | 1 | 0 | No | No |
| 17042043 | METHODS OF MANUFACTURING GENETICALLY-MODIFIED LYMPHOCYTES | September 2020 | April 2025 | Abandon | 55 | 2 | 0 | No | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner STUART, CAREY ALEXANDER MC.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner STUART, CAREY ALEXANDER MC works in Art Unit 1671 and has examined 37 patent applications in our dataset. With an allowance rate of 70.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 42 months.
Examiner STUART, CAREY ALEXANDER MC's allowance rate of 70.3% places them in the 25% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by STUART, CAREY ALEXANDER MC receive 1.59 office actions before reaching final disposition. This places the examiner in the 42% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by STUART, CAREY ALEXANDER MC is 42 months. This places the examiner in the 4% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +35.5% benefit to allowance rate for applications examined by STUART, CAREY ALEXANDER MC. This interview benefit is in the 86% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 50.0% of applications are subsequently allowed. This success rate is in the 97% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 70.0% of cases where such amendments are filed. This entry rate is in the 90% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.